Skip to content
  1. Home
  2. Medications & hormones
  3. Tadalafil

Tadalafil

An FDA-approved phosphodiesterase-5 inhibitor used to treat erectile dysfunction, benign prostatic hyperplasia, and pulmonary hypertension.

Medications & hormones

Sexual health

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

Tadalafil

An FDA-approved phosphodiesterase-5 inhibitor used to treat erectile dysfunction, benign prostatic hyperplasia, and pulmonary hypertension.

Evidence category: Regulator / guideline. This describes the source category, not approval or certainty.

Regulatory statement in source: FDA-approved.

Tadalafil is a phosphodiesterase-5 (PDE5) inhibitor approved by the FDA for three indications: erectile dysfunction, benign prostatic hyperplasia symptoms, and pulmonary arterial hypertension. Marketed as Cialis (ED/BPH), Adcirca (PAH), and in low-dose daily formulation for ED. Longer half-life than sildenafil enables once-daily dosing.

Benefits reported in the imported source

  • Erectile dysfunction.
  • Benign prostatic hyperplasia symptoms.
  • Pulmonary arterial hypertension.

Risks and limits

  • Headache
  • Flushing
  • Dyspepsia
  • Nasal congestion
  • Back pain
  • Priapism (rare)
  • Vision and hearing changes

Source bottom line: FDA-approved PDE5 inhibitor with three distinct approved indications and longer duration than sildenafil.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

No study protocol recorded in this snapshot. This does not establish that no study exists.

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

Historical research outcome: no-verified-description · 2026-10-06

No suitable community description was independently verified in these checks. The entry remains empty; this does not establish that no practice exists elsewhere.

  • https://www.nhs.uk/medicines/tadalafil/: no-practice-description — This retrieved source was checked, but no suitable community description was independently verified. Research regimens, expert advice, product identity and efficacy claims were not repurposed.

Pharmacokinetic context

Historical half-life estimate: 17.5 hours. FDA label, Cialis: mean terminal half-life 17.5 hours Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.

Source references

Snapshot provenance

Source ID: catalog:medication:tadalafil. Commit: adc7684614f9439b41d91a3312b62e7982c7e20e. Review state: historical-not-reverified. Authored links are retained separately from the canonical evidence links in the public data. App templates/defaults and rejected drafts are archived, not deployed.

Related entries and components

None listed.